

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

GOSERELIN SUSTAINED-RELEASE INJECTION (SYH9102 INJECTION) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Gonadotropin-Releasing Hormone (“**GnRH**”) receptor agonist goserelin sustained-release injection (SYH9102 injection) (the “**Product**”) developed by the Group has obtained approval from the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China.

The Product is the world’s first ready-to-use goserelin sustained-release injection approved for clinical trials. It binds to pituitary GnRH receptors with high affinity and induces receptor downregulation, thereby inhibiting gonadotropin secretion, reducing serum testosterone and oestradiol levels, and achieving medical castration. Leveraging the Group’s long-acting delivery technology platform and utilising excipients with excellent biocompatibility, the Product forms an *in situ* drug depot following subcutaneous injection, achieving long-acting drug release.

The Product is administered once monthly. Compared with marketed long-acting goserelin products, the Product utilises a finer injection needle, requires no specialised implantation needle or complex preparation procedures, and has a smaller injection volume. It is expected to significantly reduce local tissue injury and pain at the injection site, enhancing convenience of clinical application and patient medication compliance. Preclinical studies demonstrated that the Product exhibited a significant and prolonged efficacy in suppressing plasma testosterone. Compared with the commercially available microsphere formulation, it exhibited superior pharmacological efficacy in terms of testosterone castration rate and the duration of castration, along with a favourable safety profile.

The clinical indication in this approval is for patients with solid tumours. Furthermore, the Product can also be used for oestrogen-dependent diseases such as endometriosis, offering broad prospects for clinical development. The clinical trial approval of the Product marks another important achievement for the Company in the field of long-acting formulations, laying a solid foundation for the expansion of the product pipeline of this platform.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 9 September 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.